Meeting
2022 ASCO Genitourinary Cancers Symposium
Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial.
Authors
Amar Upadhyaya Kishan
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
Amar Upadhyaya Kishan , James Lamb , Maria Casado , Xiaoyan Wang , Ting Martin Ma , Daniel Low , Ke Sheng , Yingli Yang , Yu Gao , Vincent Basehart , Minsong Cao , Michael L. Steinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04384770
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 255)
DOI
10.1200/JCO.2022.40.6_suppl.255
Abstract #
255
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial.
First Author: Amar Upadhyaya Kishan
Poster
2023 ASCO Genitourinary Cancers Symposium
Two-fraction stereotactic MRI-guided ablative radiotherapy with simultaneous boost to dominant intraprostatic lesion: Results from the 2SMART phase 2 trial.
First Author: Wee Loon Ong
Poster
2020 Genitourinary Cancers Symposium
A prospective comparison of MRI-planned versus CT-planned radiotherapy for prostate cancer.
First Author: Daniel R Schmidt
Poster
2024 ASCO Genitourinary Cancers Symposium
Pretreatment colonoscopy impact on acute gastrointestinal (GI) toxicity following curative stereotactic body radiation therapy (SBRT) for localized prostate cancer.
First Author: Jonathan W. Lischalk